Pluristem Therapeutics Inc (PSTI)

[zzaatt]

Maybe if their data could pass the smell test with the NEJM, JAMA, BLOOD, ETAL.
these revered journals don't publish Company Funded, studies with "consultant" investigators.

Astonishing lack of knowledge! I just spent about two minutes to find definitive contradiction of "Auto1"'s erroneous assertion! I highlighted the first few authors getting CONSULTING FEES! It's the way it works! Spend at least some time reading research papers in "NEJM, JAMA, BLOOD, ETAL." BEFORE posting false claims.

The very first paper in the current issue of New England Journal of Medicine turned up the following:
(EVERY single author received "consulting fees"!!!!!)

LINK:
https://www.nejm.org/toc/nejm/medical-journal?query=PPC_SL&gclid=EAIaIQobChMIts6MxvfT3QIVjUwNCh0u1AH9EAAYASABEgKGwPD_BwE

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

Dr. Bohula reports receiving lecture fees from Servier, grant support and advisory board fees from Merck, consulting fees from Lexicon and MD Conference Express, fees for continuing medical education from Medscape, Academic CME, and Paradigm, advisory board fees from Novartis, and grant support from Amgen and AstraZeneca;

Dr. Wiviott, receiving grant support from Amgen and Sanofi Aventis, grant support and consulting fees from Arena, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Eli Lilly, Janssen, Merck, and AstraZeneca, and consulting fees from Aegerion, Allergan, Angelmed, Boehringer Ingelheim, Boston Clinical Research Institute, Icon Clinical, Lexicon, St. Jude Medical, and Xoma;

Dr. McGuire, receiving fees for serving on a clinical trial executive committee and consulting fees from Boehringer Ingelheim, Sanofi US, Novo Nordisk, and AstraZeneca, fees for serving on a clinical trial data monitoring committee from Janssen Research and Development and GlaxoSmithKline, fees for serving on a clinical trial executive committee and advisory board fees from Merck Sharp and Dohme, consulting fees from Eli Lilly and Metavant, fees for serving as clinical trials chair from Lexicon, fees for serving on a clinical trial executive committee from Eisai, fees for serving on a clinical trial steering committee from Esperion, and fees for serving on a clinical trial scientific advisory committee from Pfizer; Dr. Inzucchi, receiving advisory fees from Merck, Janssen, Alere, and vTv Therapeutics, fees for serving on a clinical trial steering committee and medical writing support from Boehringer Ingelheim, fees for serving on a clinical trial executive committee from AstraZeneca, fees for serving on a clinical trial steering committee from Novo Nordisk, Sanofi/Lexicon, and Daiichi Sankyo, and fees for serving as data monitoring committee member and chair from Intarcia Therapeutics; Dr. Fanola, receiving advisory board fees and travel support from Janssen; Dr. Budaj, receiving an investigator’s fee, consulting fees, and lecture fees from AstraZeneca, Sanofi Aventis, Bristol-Myers Squibb/Pfizer, Novartis, and GlaxoSmithKline and consulting fees and lecture fees from Bayer; Dr. Leiter, receiving grant support, advisory fees, and lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, and Sanofi, advisory fees and lecture fees from Servier, and grant support from GlaxoSmithKline; Dr. White, receiving grant support and fees for serving as an executive committee member and national coordinator of the ACCELERATE study from Eli Lilly, grant support and fees for serving as a steering committee member and national leader of the STRENGTH trial from Omthera Pharmaceuticals, grant support and fees for serving on a steering committee from Pfizer New Zealand, grant support and fees for serving as a steering committee member and national leader of the dal-GenE Study from DalCor Pharmaceuticals, advisory board fees from Sirtex and Acetelion, grant support and fees for serving as a steering committee member and national country lead for the AEGIS-II study, grant support and fees for serving on a steering committee from Luitpold Pharmaceuticals, grant support and fees for serving as an executive committee member and national coordinator of ODYSSEY from Sanofi Aventis, and advisory board fees, lecture fees, and travel support from AstraZeneca; Drs. Patel, Francis, and Miao, being employed by Eisai; Dr. Bonaca, receiving grant support, paid to Brigham and Women’s Hospital, and consulting fees from Amgen, AstraZeneca, and Merck, consulting fees from Aralez, Bayer, Janssen, and Sanofi, and grant support, paid to Brigham and Women’s Hospital, from MedImmune and Pfizer; Dr. Ruff, receiving grant support and consulting fees from Boehringer Ingelheim and Daiichi Sankyo and consulting fees from Bayer, Janssen, and Portola; Dr. Keech, receiving grant support, honoraria, and advisory fees from Abbott, honoraria and advisory fees from Amgen, lecture fees from AstraZeneca, Pfizer, and Bayer, grant support and honoraria from Mylan, and grant support from Sanofi and Novartis; Dr. Smith, being previously employed by Eisai; Dr. Sabatine, receiving grant support, paid to Brigham and Women’s Hospital, and consulting fees from Amgen, AstraZeneca, Intarcia Therapeutics, Janssen Research and Development, the Medicines Company, MedImmune, Merck, and Novartis, grant support, paid to Brigham and Women’s Hospital, from Daiichi Sankyo, Eisai, GlaxoSmithKline, Pfizer, Poxel, Takeda, Abbott Laboratories, Critical Diagnostics, Genzyme, Gilead, and Roche Diagnostics, and consulting fees from Bristol-Myers Squibb, CVS Caremark, Dyrnamix, Esperion, Alnylam, Ionis, and MyoKardia; Dr. Scirica, receiving grant support, paid to Brigham and Women’s Hospital, and consulting fees from AstraZeneca and Merck, grant support, paid to Brigham and Women’s Hospital, from Novartis, consulting fees from Biogen Idec, Boehringer Ingelheim, Covance, Dr. Reddy’s Laboratories, Eisai, Elsevier PracticeUpdate Cardiology, GlaxoSmithKline, Novo Nordisk, Sanofi, and St. Jude Medical, and equity from Health at Scale. No other potential conflict of interest relevant to this article was reported.

Drs. Bohula and Wiviott and Drs. Sabatine and Scirica contributed equally to this article.

This article was published on August 26, 2018, at NEJM.org.